Review Article

Pediatric Drugs

, Volume 16, Issue 3, pp 213-227

Overview of Therapy and Strategies for Optimizing Outcomes in De Novo Pediatric Acute Myeloid Leukemia

  • Kelly FaulkAffiliated withDepartment of Pediatrics, University of Colorado School of Medicine/Anschutz Medical CampusChildren’s Hospital Colorado
  • , Lia GoreAffiliated withDepartment of Pediatrics, University of Colorado School of Medicine/Anschutz Medical CampusChildren’s Hospital ColoradoUniversity of Colorado Cancer CenterDevelopmental Therapeutics Program
  • , Todd CooperAffiliated withAflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta/Emory University Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Although acute myelogenous leukemia (AML) accounts for <20 % of leukemia in children, it is responsible for over half of all pediatric leukemia deaths. Improvement in event-free survival rates, now over 50 %, are due largely to intensification of chemotherapy, aggressive supportive care, development of risk stratification based on cytogenetic and molecular markers, and improved salvage regimens. Despite this improvement over the past few decades, the survival rates have recently plateaued, and further improvement will need to take into account advances in molecular characterization of AML, development of novel agents, and better understanding of host factors influencing toxicity and response to chemotherapy. This article reviews the epidemiology and biology trends in diagnosis and treatment of pediatric acute myelogenous leukemia.